Therapeutic startup Celularity announced Thursday morning that it has received US FDA approval to begin clinical trials of a proposed stem cell treatment for coronavirus.
The human placenta contains stem cells (hematopoietic stem cells and mesenchymal stem cells). As you may know, umbilical cord blood contains many hematopoietic stem cells and is very important for hematopoietic stem cell transplantation.
Hematopoietic stem cells are the source of all blood. All cells flowing through blood vessels, such as red blood cells, white blood cells, and platelets, are differentiated from hematopoietic stem cells.
Among them are immune cells called NK cells. NK cells are immune cells that attack and eliminate foreign substances, pathogens, and viruses that invade the body.
A clinical trial was planned to see if it was effective when used to treat coronavirus infections, and the FDA, an American government agency equivalent to Japan's Ministry of Health, Labor and Welfare, granted approval.
It will be administered to up to 86 patients from now on.
Quoted from:
[New York Times news article]
Quoted from:
[Forbs article]
https://www.forbes.com/sites/alexknapp/2020/04/02/fda-gives-green-light-to-test-a-treatment-against-covid-19-coronavirus-that-flattens-the- curve-in-patients/#7a55a1354b57
Quoted from:
[Interview video between the developer and the mayor of New York City]
